CytomX Therapeutics Inc

NASDAQ:CTMX  
1.55
-0.07 (-4.32%)
7:18:54 PM EDT: $1.56 +0.01 (+0.65%)
Products, Strategic Combinations

Cytomx And Regeneron Announce Strategic Research Collaboration In The Field Of Conditional Bispecific Therapeutics For The Treatment Of Cancer

Published: 11/17/2022 12:47 GMT
CytomX Therapeutics Inc (CTMX) - Cytomx and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer.
Regeneron - Cytomx to Receive $30 Million Upfront Payment With Potential for Up to $2 Billion in Research, Development, Regulatory and Sales-based Milestones.
Regeneron Pharmaceuticals Inc - Cytomx is Also Eligible to Receive Tiered Global Net Sales Royalties.